Equities

China Traditional Chinese Medicine Holdings Co Ltd

China Traditional Chinese Medicine Holdings Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)4.35
  • Today's Change0.02 / 0.46%
  • Shares traded8.64m
  • 1 Year change+33.44%
  • Beta0.7331
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

China Traditional Chinese Medicine Holdings Co. Limited is principally engaged in the manufacture and sales of traditional Chinese medicine (TCM). The Company operates through 12 subsidiaries, including Sinopharm Group Dezhong (Foshan) Pharmaceutical Co., Ltd., Sinopharm Group Feng Liao Xing (Foshan) Pharmaceutical Co., Ltd., Sinopharm Group Guangdong Medi-World Pharmaceutical Co., Ltd., Sinopharm Group Luya (Shandong) Pharmaceutical Co., Ltd., Sinopharm Group Feng Liao Xing (Foshan) Medicinal Material & Slices Co., Ltd., Foshan Winteam Pharmaceutical Sales Company Limited, Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Sinopharm Group Jingfang (Anhui) Pharmaceutical Co., Ltd., Sinopharm Group Longlife (Guizhou) Pharmaceutical Co., Ltd., Qinghai Pulante Pharmaceutical Co., Ltd., Guizhou Zhongtai Biological Technology Company Limited and its subsidiaries and Jiangyin Tianjiang Pharmaceutical Co., Ltd. and its subsidiaries.

  • Revenue in HKD (TTM)18.97bn
  • Net income in HKD1.01bn
  • Incorporated1992
  • Employees17.30k
  • Location
    China Traditional Chinese Medicine Holdings Co LtdRoom 1601, Emperor Group Centre288 Hennessy RoadWanchai Hong KongHKG
  • Phone+852 28543393
  • Fax+852 25441269
  • Websitehttps://www.china-tcm.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Luye Pharma Group Ltd6.96bn849.73m11.36bn5.27k13.370.79126.641.630.22590.22591.853.820.2362.442.841,321,269.003.112.805.474.4568.7370.5313.1810.391.202.960.401611.822.703.50-11.94-16.39-14.05--
Shanghai Henlius Biotech Inc6.22bn763.57m12.53bn3.55k16.454.4110.702.011.401.4011.405.230.57641.906.821,710,433.007.07-8.5914.25-14.1473.2371.7712.27-27.370.3296.860.6113--67.82273.51178.53--49.14--
3SBio Inc9.29bn1.83bn13.65bn5.61k7.590.85396.021.470.75090.75093.816.680.35751.526.731,716,495.007.257.4410.269.2985.9482.9120.2721.501.5723.870.1998--13.8411.26-19.133.948.78--
Grand Pharmaceutical Group Ltd10.59bn2.41bn15.37bn10.78k6.290.97785.341.450.68850.68853.034.430.44723.623.211,005,064.0010.2510.0914.2114.0159.0061.9722.9222.351.09--0.223226.9410.1212.06-9.5921.415.6924.77
Simcere Pharmaceutical Group Ltd6.99bn-1.22bn15.79bn7.03k--2.15--2.26-0.4648-0.46482.722.910.51982.192.64995,369.40-9.0410.17-11.7115.6077.0278.82-17.4017.501.880.47090.146146.684.497.92-23.22-0.521323.93--
The United Laboratories Intl. Hldgs Ltd.15.45bn3.21bn15.83bn15.00k4.931.064.131.021.771.778.508.210.65783.303.541,030,028.0013.657.8920.7212.6446.1544.1720.7512.731.72--0.153228.9921.2212.8470.8531.6624.1946.04
Zai Lab Ltd2.52bn-2.33bn16.40bn2.18k--2.94--6.52-2.39-2.392.595.590.30833.045.52---28.50-37.72-34.92-42.7263.1764.75-92.44-282.443.29--0.0908--24.03360.0324.51---3.45--
China Medical System Holdings Ltd7.74bn1.53bn19.08bn5.78k12.461.0810.732.470.62760.62763.167.260.3842.895.651,356,928.007.5118.448.5321.1474.1375.4719.5634.263.97--0.066740.14-12.438.08-26.335.3538.695.19
China Traditional Chinese Med Hldg CoLtd18.97bn1.01bn21.91bn17.30k21.650.92949.491.150.20090.20093.774.680.4531.541.761,096,593.002.624.604.017.0749.8657.075.779.771.516.630.180817.3526.699.9968.11-2.24-12.75--
HUTCHMED (China) Ltd4.76bn-327.14m23.70bn1.97k--4.11--4.98-0.3893-0.38935.526.620.47757.104.152,394,864.00-3.30-14.35-4.65-20.4341.6736.57-6.91-31.442.68--0.0984--96.5231.38127.93--38.65--
WuXi XDC Cayman Inc3.08bn655.72m24.22bn1.50k37.473.6632.217.860.5390.5392.735.510.558621.312.622,617,298.0011.88--15.43--30.96--21.27--4.02204.820.0113--114.44--82.07------
China Resources Pharmaceutical Group Ltd276.33bn4.16bn31.29bn72.76k7.510.58652.450.11320.66270.662743.988.490.9666.093.003,786,016.003.193.0212.1311.3515.7815.723.312.871.1211.500.439624.7312.168.8610.112.8013.587.05
Data as of Sep 20 2024. Currency figures normalised to China Traditional Chinese Medicine Holdings Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

25.95%Per cent of shares held by top holders
HolderShares% Held
Ping An of China Asset Management (Hong Kong) Co., Ltd.as of 31 Dec 2023604.30m12.00%
UBS Asset Management Switzerland AGas of 26 Aug 2024386.60m7.68%
The Vanguard Group, Inc.as of 04 Sep 202492.71m1.84%
Dimensional Fund Advisors LPas of 05 Sep 202473.72m1.46%
Bosera Asset Management Co., Ltd.as of 31 Dec 202357.20m1.14%
BlackRock Fund Advisorsas of 05 Sep 202432.39m0.64%
UBS Asset Management (Americas) LLCas of 26 Aug 202423.92m0.48%
HuaAn Fund Management Co., Ltd.as of 31 Dec 202319.11m0.38%
BlackRock Advisors (UK) Ltd.as of 05 Sep 20248.70m0.17%
E Fund Asset Management Co. Ltd.as of 30 Jun 20248.14m0.16%
More ▼
Data from 30 Jun 2024 - 20 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.